Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 122

1.

Preparing Fellows for Graduation: Perspectives on Career Guidance.

LaCasce A, Graff S, Gao J, Close J, Boulmay B.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:609-614. doi: 10.1200/EDBK_242603. Epub 2019 May 17.

PMID:
31099656
2.

Psoriasiform eruptions secondary to phosphoinositide 3-kinase inhibition.

Dewan AK, Gupta S, Bach DQ, Jadeja S, Granter S, LaCasce A, Joyce R, Davids MS, Huang V, LeBoeuf NR.

JAAD Case Rep. 2019 Apr 20;5(5):401-405. doi: 10.1016/j.jdcr.2018.03.005. eCollection 2019 May. No abstract available.

3.

PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation.

Armand P, Chen YB, Redd RA, Joyce RM, Bsat J, Jeter E, Merryman RW, Coleman KC, Dahi PB, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Patel SS, Ritz J, Rodig SJ, Shipp MA, Herrera AF.

Blood. 2019 Apr 5. pii: blood.2019000215. doi: 10.1182/blood.2019000215. [Epub ahead of print]

PMID:
30952672
4.

Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders.

Crombie JL, LaCasce AS.

Front Oncol. 2019 Mar 7;9:109. doi: 10.3389/fonc.2019.00109. eCollection 2019. Review.

5.

AIDS-Related Kaposi Sarcoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Reid E, Suneja G, Ambinder RF, Ard K, Baiocchi R, Barta SK, Carchman E, Cohen A, Crysler OV, Gupta N, Gustafson C, Hall A, Johung KL, Klopp A, LaCasce AS, Lin C, Mehta A, Menon MP, Morgan D, Nathwani N, Noy A, Ratner L, Rizza S, Rudek MA, Sanchez J, Taylor J, Tomlinson B, Wang CJ, Yendamuri S, Dwyer MA; CGC, Freedman-Cass DA.

J Natl Compr Canc Netw. 2019 Feb;17(2):171-189. doi: 10.6004/jnccn.2019.0008.

PMID:
30787130
6.

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.

Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S, Lechowicz MJ, Gaur R, Lucas A, Melani C, Roschewski M, Steinberg SM, Jaffe ES, Kahl B, Friedberg JW, Little RF, Bartlett NL, Wilson WH.

Lancet Haematol. 2018 Dec;5(12):e609-e617. doi: 10.1016/S2352-3026(18)30177-7.

PMID:
30501868
7.

Current considerations in AYA Hodgkin lymphoma.

Crombie JL, LaCasce AS.

Br J Haematol. 2019 Jan;184(1):72-81. doi: 10.1111/bjh.15640. Epub 2018 Nov 20. Review.

PMID:
30460695
8.

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.

Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, Tran T, Lynn J, Chen JY, Volkmer JP, Agoram B, Huang J, Majeti R, Weissman IL, Takimoto CH, Chao MP, Smith SM.

N Engl J Med. 2018 Nov 1;379(18):1711-1721. doi: 10.1056/NEJMoa1807315.

PMID:
30380386
9.

Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia.

Davids MS, Kim HT, Yu L, De Maeyer G, McDonough M, Vartanov AR, Langey R, Fernandes SM, Hellman JM, Francoeur K, Arnason J, Jacobsen ED, LaCasce AS, Fisher DC, Brown JR.

Leuk Lymphoma. 2019 May;60(5):1312-1315. doi: 10.1080/10428194.2018.1519814. Epub 2018 Oct 15.

PMID:
30322319
10.

Reply to H.J.A. Adams et al.

Merryman RW, LaCasce A.

J Clin Oncol. 2018 Sep 17:JCO1800851. doi: 10.1200/JCO.18.00851. [Epub ahead of print] No abstract available.

PMID:
30222482
11.

Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.

Reid E, Suneja G, Ambinder RF, Ard K, Baiocchi R, Barta SK, Carchman E, Cohen A, Gupta N, Johung KL, Klopp A, LaCasce AS, Lin C, Makarova-Rusher OV, Mehta A, Menon MP, Morgan D, Nathwani N, Noy A, Palella F, Ratner L, Rizza S, Rudek MA, Taylor J, Tomlinson B, Wang CJ, Dwyer MA, Freedman-Cass DA.

J Natl Compr Canc Netw. 2018 Aug;16(8):986-1017. doi: 10.6004/jnccn.2018.0066.

PMID:
30099375
12.

Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility.

Craig JW, Mina MJ, Crombie JL, LaCasce AS, Weinstock DM, Pinkus GS, Pozdnyakova O.

PLoS One. 2018 Jul 18;13(7):e0199708. doi: 10.1371/journal.pone.0199708. eCollection 2018.

13.

Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL.

Pinnix CC, Ng AK, Dabaja BS, Milgrom SA, Gunther JR, Fuller CD, Smith GL, Abou Yehia Z, Qiao W, Wogan CF, Akhtari M, Mawlawi O, Medeiros LJ, Chuang HH, Martin-Doyle W, Armand P, LaCasce AS, Oki Y, Fanale M, Westin J, Neelapu S, Nastoupil L.

Blood Adv. 2018 Jun 12;2(11):1334-1343. doi: 10.1182/bloodadvances.2018017681.

14.

Response-Adapted Therapy in Aggressive Lymphoma: Not Yet Ready for Clinical Care.

Merryman RW, LaCasce AS.

J Clin Oncol. 2018 Jul 10;36(20):2009-2011. doi: 10.1200/JCO.2018.78.9362. Epub 2018 May 22. No abstract available.

PMID:
29787359
15.

Human Herpes Virus 8 in HIV-1 infected individuals receiving cancer chemotherapy and stem cell transplantation.

Hogan LE, Hanhauser E, Hobbs KS, Palmer CD, Robles Y, Jost S, LaCasce AS, Abramson J, Hamdan A, Marty FM, Kuritzkes DR, Henrich TJ.

PLoS One. 2018 May 10;13(5):e0197298. doi: 10.1371/journal.pone.0197298. eCollection 2018.

16.

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.

LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, Ansell SM, Crosswell HE, Islas-Ohlmayer M, Behler C, Cheung E, Forero-Torres A, Vose J, O'Connor OA, Josephson N, Wang Y, Advani R.

Blood. 2018 Jul 5;132(1):40-48. doi: 10.1182/blood-2017-11-815183. Epub 2018 Apr 27.

17.

Brentuximab Vedotin for Stage III or IV Hodgkin’s Lymphoma.

Canellos GP, LaCasce AS.

N Engl J Med. 2018 Apr 19;378(16):1560. doi: 10.1056/NEJMc1802363. No abstract available.

PMID:
29671468
18.

Adolescent and young adult lymphoma: collaborative efforts toward optimizing care and improving outcomes.

Kahn JM, Ozuah NW, Dunleavy K, Henderson TO, Kelly K, LaCasce A.

Blood Adv. 2017 Oct 10;1(22):1945-1958. doi: 10.1182/bloodadvances.2017008748. eCollection 2017 Oct 10. Review.

19.

Excellent Outcomes Following Response-based Omission of Radiotherapy in Children and Adolescents With Intermediate or High-risk Hodgkin Lymphoma.

Ozuah NW, Marcus KJ, LaCasce AS, Billett AL.

J Pediatr Hematol Oncol. 2018 Aug;40(6):e338-e342. doi: 10.1097/MPH.0000000000001076.

PMID:
29293187
20.

Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis.

Sun L, Li S, El-Jawahri A, Armand P, Dey BR, Fisher DC, Jacobsen ED, Jacobson CA, LaCasce AS, McAfee SL, Spitzer TR, Chen YB, DeFilipp Z.

Oncologist. 2018 May;23(5):624-630. doi: 10.1634/theoncologist.2017-0499. Epub 2017 Dec 28.

Supplemental Content

Loading ...
Support Center